DUPIXENT® (dupilumab) HCP Website
dupixent® (dupilumab) is a dual inhibitor of il-4 and il-13 signaling and is approved for 6 indications. the mechanism of dupilumab action has not been definitively established. serious adverse reactions may occur. please see important safety information and full prescribing information on website.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 153.527 |
| 2025-03 | 163.63 |
| 2025-04 | 133.688 |
| 2025-05 | 138.219 |
| Source | Traffic Share |
|---|---|
| search | 54.35% |
| direct | 32.21% |
| referrals | 10.48% |
| paid referrals | 2.30% |
| social | 0.60% |
| 0.06% |
| Region | Percentage |
|---|---|
| United States | 87.07% |
| Canada | 4.66% |
| United Kingdom | 3.87% |
| India | 2.56% |
| HU | 0.96% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| dupixent | 14,884 | 148,840 | $23.35 |
| dupixent copay card | 186 | 1,860 | $3.56 |
| dupixent 300 mg/2 ml subcutaneous pen injector loading dose : inject 600 mg subq route | 0 | 0 | $0.00 |
| dupixent myway | 71 | 710 | $0.00 |
| eczema in babies treatment | 34 | 340 | $0.00 |